Moleculin Biotech (MBRX) announced it has entered into research and material transfer agreement with the University of North Carolina at Chapel Hill for investigator-initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer. Under the terms of the agreement Moleculin will supply Annamycin and William Zamboni, PharmD, PhD, professor at the UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, and Carolina Institute of Nanomedicine will conduct the planned preclinical research as part of a series of funded grants. The studies covered under this agreement will evaluate the ability of novel treatment agents and modalities to enhance the tumor delivery of liposomal Annamycin and Free-Annamycin as compared to Doxil and Free-doxorubicin in the PDAC GEMM models.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Releases New Corporate Presentation
- Moleculin Biotech Secures Australian Patent for Annamycin
- Moleculin Biotech announces new Australian patent for Annamycin
- Moleculin Biotech’s Promising AML Study: A Closer Look
- Promising Developments in Moleculin Biotech’s Annamycin Drive Buy Rating